Advancements in Pancreatic Cancer Treatment: Hudson Alpha's Report
Scientists at the HudsonAlpha Institute for Biotechnology in Alabama have identified a gene, ANGPTL4, that could potentially reverse pancreatic cancer's resistance to chemotherapy. By using CRISPR to slow down the reproduction of the gene, researchers found that cancer cells became more sensitive to treatment and had reduced ability to migrate. This discovery could lead to the development of new treatments for pancreatic cancer, which has a low survival rate due to its difficulty in diagnosis and high treatment resistance.